Drug
Umbralisib
Umbralisib: highest development phase Phase 2, developed by TG Therapeutics, United Therapeutics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- TG Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Umbralisib NCT02742090 | Phase 2 | Chronic Lymphocytic Leukemia |
| Umbralisib NCT04163718 | Phase 2 | Chronic Lymphocytic Leukemia |
| Umbralisib NCT04149821 | Phase 2 | Chronic Lymphocytic Leukemia |
| Umbralisib NCT03364231 | Phase 2 | Marginal Zone Lymphoma |
| Umbralisib NCT02535286 | Phase 1 | Chronic Lymphocytic Leukemia |
Latest
No recent events.
Follow Umbralisib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.